Share this article on:

CONTRIBUTORS

doi: 10.1212/01.CON.0000512908.17826.e5
Contributors

Kevin M. Barrett, MD, MSc, Guest Editor

Associate Professor, Vice Chair, Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida

aDr Barrett serves on the editorial board of Neurology, has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials, and receives publishing royalties from Wiley Blackwell.

bDr Barrett reports no disclosure.

Samir R. Belagaje, MD

Assistant Professor of Neurology and Rehabilitation Medicine, Emory University School of Medicine; Director of Stroke Rehabilitation, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Atlanta, Georgia

aDr Belagaje reports no disclosure.

bDr Belagaje discusses the unlabeled/investigational use of fluoxetine for poststroke motor recovery treatment, cholinesterase inhibitors and memantine for the treatment of aphasia, and dopaminergic agents to aid in the treatment of poststroke depression.

Cheryl Bushnell, MD, MHS

Professor of Neurology, Director, Wake Forest Baptist Comprehensive Stroke Center, Wake Forest Baptist Health, Winston Salem, North Carolina

aDr Bushnell receives research/grant support from the Patient-Centered Outcomes Research Institute (PCS-1403-14532).

bDr Bushnell reports no disclosure.

John W. Cole, MD, MS

Staff Physician, Neurology, Baltimore Veterans Affairs Medical Center; Associate Professor, Neurology, University of Maryland School of Medicine, Baltimore, Maryland

aDr Cole receives research/grant support from the American Heart Association (15GPSPG23770000) and the National Institutes of Health (1U01NS069208), which partially funded the writing of this article.

bDr Cole reports no disclosure.

Shelagh B. Coutts, MD, MSc, FRCPC

Stroke Neurologist; Associate Professor, Departments of Clinical Neuroscience, Radiology, Community Health Sciences, University of Calgary, Hotchkiss Brain Institute, Calgary, Alberta, Canada

aDr Coutts receives research/grant support from the Canadian Institutes of Health Research, (CRH-112319), the Heart and Stroke Foundation of Canada (G-16-00012585), and Genome Canada (143TIA-Penn).

bDr Coutts reports no disclosure.

Bart M. Demaerschalk, MD, MSc, FAHA, FRCPC

Professor of Neurology, Mayo College of Medicine, Phoenix, Arizona

aDr Demaerschalk has received personal compensation as editor-in-chief of The Neurologist and has received publishing royalties from Springer Publishing Company and John Wiley & Sons, Inc.

bDr Demaerschalk reports no disclosure.

Kelly D. Flemming, MD

Consultant in Department of Neurology; Associate Professor of Medicine, Mayo Clinic, Rochester, Minnesota

aDr Flemming reports no disclosure.

bDr Flemming discusses the unlabeled/investigational use of statins and fasudil for the treatment of cavernous malformation.

Amy Guzik, MD

Assistant Professor, Neurology, Wakeforest Baptist Medical Center, Winston Salem, North Carolina

a,bDr Guzik reports no disclosures.

Josephine F. Huang, MD

Instructor of Neurology, Mayo Clinic, Jacksonville, Florida

aDr Huang reports no disclosure.

bDr Huang discusses the unlabeled/investigational use of tranexamic acid and ε-aminocaproic acid for intracranial hemorrhage.

David Y. Hwang, MD

Assistant Professor, Division of Neurocritical Care and Emergency Neurology, Yale School of Medicine; Neurointensivist, Yale-New Haven Hospital, New Haven, Connecticut

aDr Hwang has received personal compensation for speaking engagements for the Mayo Clinic and The Pennsylvania State University and research/grant support from the American Brain Foundation, the Apple Pickers Foundation, the Neurocritical Care Society, and the National Institute on Aging, via its Loan Repayment Program.

bDr Hwang reports no disclosure.

William Jones, MD

Associate Professor of Neurology; Division Chief, Neurohospitalist and Vascular Neurology, University of Colorado, Anschutz Medical Campus, Department of Neurology, Aurora, Colorado

a,bDr Jones reports no disclosures.

Pearce J. Korb, MD

Assistant Professor of Neurology, University of Colorado, Anschutz Medical Campus, Department of Neurology, Aurora, Colorado

a,bDr Korb reports no disclosures.

Riten Kumar, MD, MSc

Assistant Professor of Pediatrics, The Ohio State University, Division of Hematology/Oncology, Nationwide Children’s Hospital, Columbus, Ohio

aDr Kumar serves on the medical advisory board of Bayer Corporation and receives research/grant support from the Hemostasis and Thrombosis Research Society (HTRS Mentored Research Award) and the International Society on Thrombosis and Haemostasis.

bDr Kumar discusses the unlabeled/investigational use of antithrombotic and thrombolytic agents in children with stroke.

Giuseppe Lanzino, MD

Professor of Neurosurgery, Mayo Clinic, Rochester, Minnesota

aDr Lanzino serves as a consultant for Medtronic.

bDr Lanzino discusses the unlabeled/investigational use of statins and fasudil for the treatment of cavernous malformation.

Warren D. Lo, MD

Clinical Professor, Departments of Pediatrics and Neurology, Ohio State University; Pediatric Neurologist, Nationwide Children’s Hospital, Columbus, Ohio

aDr Lo receives research/grant support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5R01HD068345, 1R01HD074574, R01HD083384) and the National Institute of Neurological Disorders and Stroke (U10NS086484, U54 NS065705) and receives publishing royalties from Springer.

bDr Lo discusses the unlabeled/investigational use of antithrombotic and thrombolytic agents in children with stroke.

Jennifer Juhl Majersik, MD, MS

Associate Professor of Neurology; Director, Stroke Center and Telestroke Services; Chief, Division of Vascular Surgery, University of Utah, Salt Lake City, Utah

aDr Majersik receives research/grant support from the National Institutes of Health (5U10NS086606) and Remedy Pharmaceuticals, Inc. Dr Majersik has served as an expert witness for FAVROS PLLC.

bDr Majersik reports no disclosure.

Cumara B. O’Carroll, MD, MPH

Assistant Professor of Neurology, Mayo Clinic, Phoenix, Arizona

a,bDr O’Carroll reports no disclosures.

Alejandro A. Rabinstein, MD, FAAN

Professor of Neurology, Mayo Clinic, Rochester, Minnesota

aDr Rabinstein serves as an associate editor for Neurocritical Care; on the editorial boards of Continuum: Lifelong Learning in Neurology, the Journal of Stroke and Cerebrovascular Diseases, Neurology, and Stroke; and on the scientific advisory board of Portola Pharmaceuticals, Inc. Dr Rabinstein receives research/grant support from DJO Global, Inc, and royalties from Elsevier, Oxford University Press, and UpToDate, Inc.

bDr Rabinstein reports no disclosure.

Andrew M. Southerland, MD, MSc

Assistant Professor of Neurology and Public Health Sciences, University of Virginia Health System, Charlottesville, Virginia

aDr. Southerland serves as deputy editor of the Neurology podcast and receives research/ grant support from the American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources & Services Administration (HRSA GO1RH27869-01-00), and the National Institute of Neurological Disorders and Stroke (U01 NS069498).

bDr Southerland reports no disclosure.

Douglas J. Gelb, MD, PhD, FAAN

Professor of Neurology, University of Michigan, Ann Arbor, Michigan

aDr Gelb receives royalties from Oxford University Press and UpToDate, Inc.

bDr Gelb reports no disclosure.

Adam Kelly, MD

Associate Professor of Neurology, University of Rochester Medical Center; Chief of Neurology, Highland Hospital, Rochester, New York

aDr Kelly has received research support from the Donald W. Reynolds Foundation.

bDr Kelly reports no disclosure

© 2017 American Academy of Neurology